Dong-A ST's New Drug Development, ST Pharm's Oligonucleotide CDMO
Vigen Leading with Biopharmaceutical CMO Capabilities

On June 17, Dong-A Socio Group announced that it will participate in the "BIO International Convention 2026," which will be held in San Diego, United States, from June 22 to 25 (local time), with the goal of expanding its global partnerships.


Aerial View of Dong-A Socio Group Booth at BIO USA 2026. Dong-A Socio Group

Aerial View of Dong-A Socio Group Booth at BIO USA 2026. Dong-A Socio Group

View original image

This event, hosted by the Biotechnology Innovation Organization (BIO), is the world's largest pharmaceutical and biotechnology exhibition, attended annually by more than 20,000 pharmaceutical and biotech professionals from over 70 countries.


At the exhibition, research and development (R&D) accomplishments and pipelines will be introduced, and a variety of business meetings will take place to attract investment, facilitate technology licensing in and out, and strengthen global partnerships.


Dong-A Socio Group will operate a joint booth featuring Dong-A ST, which focuses on new drug development; ST Pharm, specializing in integrated RNA therapy contract development and manufacturing (CDMO) services; and Vigen, which engages in biopharmaceutical contract manufacturing (CMO) business. The group plans to intensively promote each company's proprietary technologies and global market entry strategies.


At the booth, Yoonseok Oh, Executive Vice President and Head of R&D at Dong-A ST; Mujae Sung, President of ST Pharm; and Hyunmin Lee, President of Vigen, will be at the forefront, aiming to strengthen relationships with client companies.


Dong-A ST will actively showcase its innovative new drug pipeline, focusing on oncology, immune and inflammatory diseases, and neurodegenerative disorders, as well as its biosimilar business at this year's BIO USA. The company plans to pursue global technology licensing and seek joint development partners.


In particular, based on the R&D achievements of its key pipelines, Dong-A ST intends to expand strategic collaboration opportunities with global pharmaceutical and biotech companies and proactively engage in business meetings to create new business opportunities. Additionally, the company will look for open innovation activities by actively seeking opportunities to introduce promising assets from the early research stage to clinical development.


ST Pharm will highlight its high-purity, large-scale manufacturing and quality management capabilities in the oligonucleotide field, from early clinical to commercial-scale production, with the full-scale operation of its second oligonucleotide plant. The company will also showcase its 'xRNA Platform' system, which can meet the technology demands of next-generation RNA therapeutics, as well as its proprietary 5' capping technology 'SmartCap®' and LNP formulation technology 'STLNP®' to demonstrate its mRNA-LNP CDMO capabilities.


Vigen, which was recently selected by the National Growth Fund, plans to promote its enhanced production capacity through the expansion of its first plant. With the expansion, the bioreactor capacity will increase from the existing 9,000 liters to 14,000 liters, and the production culture capacity will also grow by approximately 55%.


Additionally, Vigen plans to showcase its competitiveness in new drug and biosimilar businesses through a dual-track strategy based on rare disease therapeutics and off-patent biopharmaceuticals over the mid- to long-term.



A Dong-A Socio Group representative stated, "We plan to introduce the competitive strengths of Dong-A ST, ST Pharm, and Vigen across the entire value chain from new drug development to production, leveraging expertise in new drug discovery, integrated RNA therapy CDMO, and biopharmaceutical CMO." The representative added, "By meeting with more client and potential client companies, we aim to further enhance our global expansion prospects."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing